4 Amendments of Maurice PONGA related to 2016/2057(INI)
Amendment 1 #
Draft opinion
Paragraph 1
Paragraph 1
1. Recalls thate 2030 Agenda for Sustainable Development Goal 3, with nine quantitative and four qualitative targets, clearly states that by 2030 everyone should have access to good mental and physical health throughout their lives; underlines that, each year, 100 million people fall into poverty because of health costs, adopted by the United Nations on 25 September 2015, and Sustainable Development Goal (SDG) No 3 thereof, to ‘Ensure healthy lives and promote well-being for all at all ages’, under which tare disproportionate to their incomget 3b is to ‘provide access to affordable essential medicines, and vaccines’; emphasises that, according to the WHO, over one third of the world’s population, with over 50 % in Africa, does not have access to medicines;
Amendment 29 #
Draft opinion
Paragraph 2
Paragraph 2
2. Urges not to use free trade agreements with low- and middle-income countries (LMICs) to introduce TRIPS- plus intellectual property (IP) rules that extend monopoly protection, and not to introduce new IP enforcement rules or investment protection to the detriment of access to medicinesDraws attention to the Declaration on the TRIPS Agreement and Public Health, adopted on 14 November 2001, which states that the TRIPS Agreement should be implemented and interpreted in a way that is good for public health – encouraging both access to existing medicines and the development of new ones; welcomes in this regard the decision by the World Trade Organisation’s TRIPS Council to extend until January 2033 the derogations for Least Developed Countries (LDCs);
Amendment 40 #
Draft opinion
Paragraph 3
Paragraph 3
3. Supports competition in generic medicines, which allows broad access to medicRecognises the importance of generic and biosimilar medicines, which make for more competition and for savinegs in LMICs; calls, in particular,the health sector; calls for the EU to support activelynot only the governments that use the available legal measures, including TRIPS safeguards and flexibilities,of developing countries with a view to protecting and promoteing public health; calls also for the EU to immediately stop targeting countries such as India that have implemented progressive TRIPS-compliant IP policies which promote access to medicines, through its watch-list of ‘priority but also the private sector in its initiatives to promote access to medicines in developing countries’;
Amendment 68 #
Draft opinion
Paragraph 5
Paragraph 5
5. Urges to takehat advantage be taken of the ongoing review process of the EU Tiered Pricing Regulation to repeal it unless itsee if the Regulation can be amendrevised, in close collaboration with the Commission’s Directorates- General for International Cooperation and Development (DG DEVCO) and for Health and Food Safety (DG SANTÉ), in orderso as to support all measures that countries have at their disposal to ensure affordable access to medicines.